Episode 38: Should Immunotherapy Be Offered For Atopic Dermatitis?

Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue! Today we are joined by Dr. Melinda Rathkopf, who is an associate professor at Emory and has had multiple leadership positions at the College, including sitting on the board of regents and chairing the Practice Management Committee. We will be reviewing the May-June 2023 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.  You can earn CME credit by listening to this podcast! For information about CME credit please visit https://education.acaai.org/allergytalk . To read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch . Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed:  Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: A randomized controlled trial.   Allergen immunotherapy for atopic dermatitis: Systematic review and meta-analysis of benefits and harms.   The impact of prenatal dog keeping on infant gut microbiota development.   Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: [email protected] ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.   Today’s speakers have the following disclosures: Drs. Lee and Rathkopf have nothing to disclose Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst